Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2026; 18(11): 125343
Published online Nov 27, 2026. doi: 10.4254/wjh.125343
Published online Nov 27, 2026. doi: 10.4254/wjh.125343
Hepatitis B surface antigen-targeting strategies for clearance: A review of progress from mechanistic exploration to clinical translation
Li Wang, Department of Hepatology, Yantai Qishan Hospital, Yantai 264001, Shandong Province, China
Li Wang, Department of Clinical Laboratory, Yantai Qishan Hospital, Yantai 264001, Shandong Province, China
Author contributions: Wang Li conceived the topic, wrote the article, drew the figures, and revised the article.
AI contribution statement: The image was drawn on the website https://jova.ai/ai-image-generator (AI tool: Jova.ai). The authors take full responsibility and accountability for all content of this manuscript, including any portions for which AI tools were used as assistive technologies. All AI-assisted outputs were carefully reviewed, validated, and approved by the authors. AI tools were not used to generate original scientific data, perform independent scientific analyses, or draw scientific conclusions.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Corresponding author: Li Wang, PhD, Associate Professor, Department of Hepatology, Yantai Qishan Hospital, No. 62 Huanshan Road, Zhifu District, Yantai 264001, Shandong Province, China. liliwang2200@163.com
Received: July 9, 2026
Revised: August 2, 2026
Accepted: October 20, 2026
Published online: November 27, 2026
Processing time: 139 Days and 1.6 Hours
Revised: August 2, 2026
Accepted: October 20, 2026
Published online: November 27, 2026
Processing time: 139 Days and 1.6 Hours
Core Tip
Core Tip: Hepatitis B surface antigen persistence is the primary driver of immune tolerance in chronic hepatitis B. Strategies that reduce or eliminate hepatitis B surface antigen to break host immune tolerance and reinvigorate an immune response are emerging as promising therapeutic avenues for clinical cure. These therapeutic modalities include monoclonal antibodies, small interfering RNAs, antisense oligonucleotides, gene-editing technologies, capsid assembly modulators, agents targeting secretory pathways, and immune-based clearance strategies. Combination strategies have shown synergistic effects. Future clinical trial designs must prioritize identifying optimal combinations that maximize synergy while minimizing toxicity.